Duloxetine's modest short-term influences in subcortical structures of first episode drug-naïve patients with major depressive disorder and panic disorder

Psychiatry Research - Neuroimaging

Volumn 194, Issue 2, 2011, Pages 157-162

  Lai, Chien Han ^a   Wu, Yu Te ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Brainstem; Duloxetine; Hippocampus; Nucleus accumbens; Putamen

Indexed keywords

DULOXETINE;

ADULT; ARTICLE; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; PANIC; PRIORITY JOURNAL; PUTAMEN; REMISSION; STRUCTURE ANALYSIS; SUBCORTEX;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN; BRAIN MAPPING; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; STATISTICS AS TOPIC; THIOPHENES;

EID: 80054076281     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2011.03.011     Document Type: Article

References (42)

1. Biederman J., Petty C., Faraone S.V., Hirshfeld-Becker D.R., Henin A., Pollack M.H., Rosenbaum J.F. Patterns of comorbidity in panic disorder and major depression: findings from a nonreferred sample. Depression and Anxiety 2005, 21:55-60.
2. Bragulat V., Paillere-Martinot M.L., Artiges E., Frouin V., Poline J.B., Martinot J.L. Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-l-dopa positron emission tomography study with voxel-based analysis. Psychiatry Research: Neuroimaging 2007, 154:115-124.
3. Caetano S.C., Hatch J.P., Brambilla P., Sassi R.B., Nicoletti M., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., Soares J.C. Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression. Psychiatry Research: Neuroimaging 2004, 132:141-147.
4. Calabrese F., Molteni R., Cattaneo A., Macchi F., Racagni G., Gennarelli M., Ellenbroek B.A., Riva M.A. Long-term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms. Molecular Pharmacology 2010, 77:846-853.
5. Cannon D.M., Ichise M., Rollis D., Klaver J.M., Gandhi S.K., Charney D.S., Manji H.K., Drevets W.C. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biological Psychiatry 2007, 62:870-877.
6. Chen M.C., Hamilton J.P., Gotlib I.H. Decreased hippocampal volume in healthy girls at risk of depression. Archives of General Psychiatry 2010, 67:270-276.
7. de Jong L.W., van der Hiele K., Veer I.M., Houwing J.J., Westendorp R.G., Bollen E.L., de Bruin P.W., Middelkoop H.A., van Buchem M.A., van der Grond J. Strongly reduced volumes of putamen and thalamus in Alzheimer's disease: an MRI study. Brain 2008, 131:3277-3285.
8. Frodl T., Jager M., Smajstrlova I., Born C., Bottlender R., Palladino T., Reiser M., Moller H.J., Meisenzahl E.M. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. Journal of Psychiatry & Neurosciences 2008, 33:423-430.
9. Geuze E., Vermetten E., Bremner J.D. MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders. Molecular Psychiatry 2005, 10:160-184.
10. Gotlib I.H., Hamilton J.P., Cooney R.E., Singh M.K., Henry M.L., Joormann J. Neural processing of reward and loss in girls at risk for major depression. Archives of General Psychiatry 2010, 67:380-387.
11. Grunhaus L., Pande A.C., Brown M.B., Greden J.F. Clinical characteristics of patients with concurrent major depressive disorder and panic disorder. The American Journal of Psychiatry 1994, 151:541-546.
12. Guest P.C., Knowles M.R., Molon-Noblot S., Salim K., Smith D., Murray F., Laroque P., Hunt S.P., De Felipe C., Rupniak N.M., McAllister G. Mechanisms of action of the antidepressants fluoxetine and the substance P antagonist L-000760735 are associated with altered neurofilaments and synaptic remodeling. Brain Research 2004, 1002:1-10.
13. Hasbi A., Fan T., Alijaniaram M., Nguyen T., Perreault M.L., O'Dowd B.F., George S.R. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:21377-21382.
14. Hasler G., Nugent A.C., Carlson P.J., Carson R.E., Geraci M., Drevets W.C. Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Archives of General Psychiatry 2008, 65:1166-1175.
15. Johnson P.L., Truitt W.A., Fitz S.D., Lowry C.A., Shekhar A. Neural pathways underlying lactate-induced panic. Neuropsychopharmacology 2008, 33:2093-2107.
16. Juric D.M., Miklic S., Carman-Krzan M. Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes. Brain Research 2006, 1108:54-62.
17. Kihara T., Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. Journal of Pharmacololgy & Experimental Therapy 1995, 272:177-183.
18. Koolschijn P.C., van Haren N.E., Lensvelt-Mulders G.J., Hulshoff Pol H.E., Kahn R.S. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Human Brain Mapping 2009, 30:3719-3735.
19. Kornhuber J., Reichel M., Tripal P., Groemer T.W., Henkel A.W., Muhle C., Gulbins E. The role of ceramide in major depressive disorder. European Archive of Psychiatry & Clinical Neuroscience 2009, 259(Suppl 2):S199-S204.
20. Lai C.H., Hsu Y.Y. A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy. International Journal of Neuropsychopharmacology 2011, 14(2):225-235.
21. Lai C.H., Hsu Y.Y., Wu Y.T. First episode drug-naive major depressive disorder with panic disorder: gray matter deficits in limbic and default network structures. European Neuropsychopharmacology 2010, 20:676-682.
22. Langenecker S.A., Kennedy S.E., Guidotti L.M., Briceno E.M., Own L.S., Hooven T., Young E.A., Akil H., Noll D.C., Zubieta J.K. Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder. Biological Psychiatry 2007, 62:1272-1280.
23. MacQueen G., Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Molecular Psychiatry 2011, 16(3):252-264.
24. Manev H., Uz T., Manev R. Glia as a putative target for antidepressant treatments. Journal of Affective Disorders 2003, 75:59-64.
25. Molteni R., Calabrese F., Cattaneo A., Mancini M., Gennarelli M., Racagni G., Riva M.A. Acute stress responsiveness of the neurotrophin BDNF in the rat hippocampus is modulated by chronic treatment with the antidepressant duloxetine. Neuropsychopharmacology 2009, 34:1523-1532.
26. Monk C.S., Klein R.G., Telzer E.H., Schroth E.A., Mannuzza S., Moulton J.L., Guardino M., Masten C.L., McClure-Tone E.B., Fromm S., Blair R.J., Pine D.S., Ernst M. Amygdala and nucleus accumbens activation to emotional facial expressions in children and adolescents at risk for major depression. The American Journal of Psychiatry 2008, 165:90-98.
27. Moresco R.M., Pietra L., Henin M., Panzacchi A., Locatelli M., Bonaldi L., Carpinelli A., Gobbo C., Bellodi L., Perani D., Fazio F. Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naive patients. Neuropsychopharmacology 2007, 32:197-205.
28. Morey R.A., Petty C.M., Xu Y., Hayes J.P., Wagner H.R., Lewis D.V., LaBar K.S., Styner M., McCarthy G. A comparison of automated segmentation and manual tracing for quantifying hippocampal and amygdala volumes. NeuroImage 2009, 45:855-866.
29. Morey R.A., Selgrade E.S., Wagner H.R., Huettel S.A., Wang L., McCarthy G. Scan-rescan reliability of subcortical brain volumes derived from automated segmentation. Human Brain Mapping 2010, 31:1751-1762.
30. Muneoka K., Shirayama Y., Takigawa M., Shioda S. Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats. Neurochemical Research 2009, 34:542-555.
31. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biological Psychiatry 2006, 59:1151-1159.
32. Neumeister A., Wood S., Bonne O., Nugent A.C., Luckenbaugh D.A., Young T., Bain E.E., Charney D.S., Drevets W.C. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biological Psychiatry 2005, 57:935-937.
33. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9:97-113.
34. Parent M.B., Master S., Kashlub S., Baker G.B. Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum. Biochemical Pharmacology 2002, 63:57-64.
35. Pizzagalli D.A., Holmes A.J., Dillon D.G., Goetz E.L., Birk J.L., Bogdan R., Dougherty D.D., Iosifescu D.V., Rauch S.L., Fava M. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. The American Journal of Psychiatry 2009, 166:702-710.
36. Protopopescu X., Pan H., Tuescher O., Cloitre M., Goldstein M., Engelien A., Yang Y., Gorman J., LeDoux J., Stern E., Silbersweig D. Increased brainstem volume in panic disorder: a voxel-based morphometric study. Neuroreport 2006, 17:361-363.
37. Seror I., Lee H., Cohen O.S., Hoffmann C., Prohovnik I. Putaminal volume and diffusion in early familial Creutzfeldt-Jakob disease. Journal of Neurological Science 2010, 288:129-134.
38. Shirayama Y., Chaki S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Current Neuropharmacology 2006, 4:277-291.
39. Walter U., Prudente-Morrissey L., Herpertz S.C., Benecke R., Hoeppner J. Relationship of brainstem raphe echogenicity and clinical findings in depressive states. Psychiatry Research: Neuroimaging 2007, 155:67-73.
40. Wells T.T., Beevers C.G., McGeary J.E. Serotonin transporter and BDNF genetic variants interact to predict cognitive reactivity in healthy adults. Journal of Affective Disorders 2010, 126:223-229.
41. Witkin J.M., Marek G.J., Johnson B.G., Schoepp D.D. Metabotropic glutamate receptors in the control of mood disorders. CNS & Neurological Disorders Drug Targets 2007, 6:87-100.
42. Yoo H.K., Kim M.J., Kim S.J., Sung Y.H., Sim M.E., Lee Y.S., Song S.Y., Kee B.S., Lyoo I.K. Putaminal gray matter volume decrease in panic disorder: an optimized voxel-based morphometry study. European Journal of Neurosciences 2005, 22:2089-2094.